SKNY — LIR Life Sciences Share Price
Last trade - 00:00- CA$15.48m
- CA$14.56m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 14.55 | ||
| Price to Tang. Book | 16.08 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -828.34% | ||
| Return on Equity | -193.59% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 30th Apr | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
LIR Life Sciences Corp. is a Canada-based company. The Company is engaged in developing therapies across multiple treatment areas, with a focus on obesity and metabolic disorders. It develops glucagon-like peptide-1 (GLP-1) based therapies for patients. It has access to a drug delivery system and plans to utilize technology to enable the needle-free administration of complex large-molecule biologics which provides a potential alternative to injectable treatments across a wide variety of treatments and diseases. The Company develops LIR001 Dual-Action Therapy (LIR001). LIR001 combines GLP-1 receptor agonists with other drugs to enhance obesity treatment by targeting both metabolic and behavioral factors. GLP-1 receptor agonists, such as liraglutide and semaglutide, regulate blood sugar, promote insulin release, and slow gastric emptying, leading to reduced appetite and improved insulin sensitivity.
Directors
- Last Annual
- April 30th, 2025
- Last Interim
- January 31st, 2026
- Incorporated
- August 31st, 2018
- Public Since
- April 11th, 2022
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Canadian Securities Exchange
- Shares in Issue
- 28,666,957
- Address
- Suite 2133-1177 West Hasting Street, VANCOUVER, V6C 3L6
- Web
- https://lirlife.com/
- Phone
- +1 6048037711
- Auditors
- DALE MATHESON CARR-HILTON LABONTE LLP
Similar to SKNY
Albert Labs International
Canadian Securities Exchange
Asep Medical Holdings
Canadian Securities Exchange
BetterLife Pharma
Canadian Securities Exchange
BioMark Diagnostics
Canadian Securities Exchange
Biovaxys Technology
Canadian Securities Exchange
FAQ
As of Today at 21:47 UTC, shares in LIR Life Sciences are trading at CA$0.54. This share price information is delayed by 15 minutes.
Shares in LIR Life Sciences last closed at CA$0.54 and the price had moved by +44% over the past 365 days. In terms of relative price strength the LIR Life Sciences share price has outperformed the Toronto Stock Exchange 300 Composite Index by +8.11% over the past year.
There is no consensus recommendation for this security.
Find out moreLIR Life Sciences does not currently pay a dividend.
LIR Life Sciences does not currently pay a dividend.
LIR Life Sciences does not currently pay a dividend.
To buy shares in LIR Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$0.54, shares in LIR Life Sciences had a market capitalisation of CA$15.48m.
Here are the trading details for LIR Life Sciences:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: SKNY
Based on an overall assessment of its quality, value and momentum LIR Life Sciences is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like LIR Life Sciences. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -40.07%.
As of the last closing price of CA$0.54, shares in LIR Life Sciences were trading -34.07% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The LIR Life Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.54.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on LIR Life Sciences' directors